Why the study?
Does BMS-182248 reduce cardiotoxicity and overall toxicity compared to free doxorubicin in Sprague-Dawley rats?
Population
Sprague-Dawley rats
Comparison
BMS-182248 (immunoglobulin-cytotoxic drug… vs Free doxorubicin at single doses of 33.6 and 72…
Design
Preclinical
Follow-up
up to approximately 3 months
Authors
Loading...
BMS-182248 shows lower toxicity than free doxorubicin in rats; hypothesis-generating and should not yet change clinical practice.
Does BMS-182248 reduce cardiotoxicity and overall toxicity compared to free doxorubicin in Sprague-Dawley rats?
BMS-182248, a doxorubicin conjugate, produces substantially less severe toxicity, notably cardiotoxicity, compared to equivalent doses of free doxorubicin in rats.
Comereski et al. (1994) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: